688575.SHG Shenzhen YHLO Biotech Co. Ltd. A
- Market cap
- CNY 6.21B
- P/E
- 60.4x
- P/B
- 2.22x
- ROE
- 6.8%
- Dividend yield
- 2.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688575.SHG undervalued?
Graham number688575.SHG trades 143.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen YHLO Biotech Co. Ltd. A fundamental analysis
No fundamental analysis for Shenzhen YHLO Biotech Co. Ltd. A yet.
Shenzhen YHLO Biotech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen YHLO Biotech Co. Ltd. A
Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. It offers chemiluminescence immunoassay analyzer, diabetes instruments and related reagents, automated biochemical analyzer, laboratory automation, tenfly phoenix blot analyzer, VISION Pro ESR analyzer, and VISION ESR analyzer. The company was founded in 2008 and is headquartered in Shenzhen, China.
Full company profileShenzhen YHLO Biotech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen YHLO Biotech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 530M | 729M | 877M | 999M | 1.18B | 3.98B | 2.05B | 2.01B | 1.81B | 1.91B |
| Gross Profit | 194M | 283M | 436M | 565M | 648M | 2.04B | 1.10B | 1.29B | 1.81B | 1.20B |
| Operating Income | 13.6M | 50.1M | 126M | 247M | 227M | 1.20B | 341M | 315M | 110M | 292M |
| EBITDA | 27.6M | 80.5M | 194M | 324M | 339M | 1.34B | 531M | 567M | 333M | 232M |
| Net Income | 5.89M | 38.0M | 108M | 211M | 205M | 1.01B | 355M | 302M | 24.0M | 191M |
| EPS | 0.01 | 0.08 | 0.21 | 0.41 | 0.38 | 1.78 | 0.62 | 0.53 | 0.04 | 0.33 |
| Balance Sheet | ||||||||||
| Total Assets | 593M | 838M | 1.08B | 1.32B | 2.14B | 4.21B | 3.81B | 4.42B | 4.29B | 4.34B |
| Total Liabilities | 298M | 506M | 497M | 559M | 624M | 1.77B | 1.27B | 1.71B | 1.60B | 1.52B |
| Shareholders' Equity | 295M | 333M | 579M | 768M | 1.53B | 2.42B | 2.56B | 2.76B | 2.70B | 2.82B |
| Cash & Short-term Investments | 85.6M | 64.2M | 151M | 232M | 495M | 1.36B | 567M | 535M | 407M | 597M |
| Total Debt | 81.4M | 235M | 271M | 307M | 234M | 474M | 557M | 880M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 8.67M | 29.7M | 68.3M | 282M | 260M | 1.58B | -64.1M | 530M | 422M | - |
| Capital Expenditure | 83.0M | 186M | 128M | 189M | 373M | 565M | 663M | 593M | 359M | 318M |
| Free Cash Flow | -74.3M | -157M | -59.8M | 92.8M | -113M | 1.02B | -736M | -63.4M | 62.6M | 190M |
| Ratios | ||||||||||
| ROE | 2.0% | 11.4% | 18.6% | 27.4% | 13.4% | 41.9% | 13.9% | 10.9% | 0.9% | 6.8% |
| ROA | 1.0% | 4.5% | 10.0% | 15.9% | 9.6% | 24.0% | 9.3% | 6.8% | 0.6% | 4.4% |
| Net Profit Margin | 1.1% | 5.2% | 12.3% | 21.1% | 17.4% | 25.4% | 17.3% | 15.0% | 1.3% | 10.0% |
| Debt to Equity | 0.28x | 0.70x | 0.47x | 0.40x | 0.15x | 0.20x | 0.22x | 0.32x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen YHLO Biotech Co. Ltd. A dividends
- Dividend yield
- 2.28%
- Forward dividend
- 0.02 CNY
- Payout ratio
- 589.4%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 142M | 0.24 | 589.4% |
| 2024 | CNY 169M | 0.30 | 56.1% |
| 2023 | CNY 256M | 0.45 | 72.0% |
| 2022 | CNY 162M | 0.28 | 16.0% |
| 2021 | CNY 10.9M | 0.02 | 5.3% |
| 2020 | CNY 21.8M | 0.04 | 10.4% |
| 2019 | CNY 1.00M | 0.00 | 0.9% |
| 2018 | 10.5M | 0.02 | 27.5% |
| 2017 | 14.3M | 0.03 | 242.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 2, 2022.
Who owns Shenzhen YHLO Biotech Co. Ltd. A
- Insiders 50.62%
- Institutions 11.39%
- Public & others 38.00%
- Shares outstanding 571M
- Free float 286M
Shenzhen YHLO Biotech Co. Ltd. A company profile
- Company name
- Shenzhen YHLO Biotech Co. Ltd. A
- Ticker
- 688575.SHG
- ISIN
- CNE100005204
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,664
- Fiscal year end
- December
- Address
- Building 1, Baolong, 2nd Road, Shenzhen, China, 518116
- Phone
- 86 755 2660 1910
- Website
- szyhlo.com
About Shenzhen YHLO Biotech Co. Ltd. A
Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. It offers chemiluminescence immunoassay analyzer, diabetes instruments and related reagents, automated biochemical analyzer, laboratory automation, tenfly phoenix blot analyzer, VISION Pro ESR analyzer, and VISION ESR analyzer. The company was founded in 2008 and is headquartered in Shenzhen, China.
Shenzhen YHLO Biotech Co. Ltd. A management
5- Mr. Yongbo SongGM & Vice Chairman of the Board · born 1984
- Mr. Lisheng LiaoCFO & Director · born 1979
- Mr. Chun Gen QianDeputy GM & Director · born 1982
- Mr. Yujing XiaoDeputy General Manager · born 1976
- Ming Min ZhaoHead of Accounting